User:Uushayallaturi

Ebola is a disease of humans and other primates caused by an ebolavirus. Symptoms start two days to three weeks after contracting the virus, with a fever, sore throat, muscle pain and headaches. Typically, vomiting, diarrhea and rash follow, along with decreased functioning of the liver and kidneys. Around this time, affected people may begin to bleed both within the body and externally. The virus may be acquired upon contact with blood or bodily fluids of an infected animal The virus uses a combination of genes to prevent the cells they infect from triggering the immune system, a team of biologists at the University of Texas Medical Branch and the U.S. National Institute of Allergy and Infectious Diseases found. People who die from Ebola generally don't seem to have had an immune response to the virus at the time of their deaths Zaire variant of the Ebola virus prevents cells called dendric cells from making proteins that call other immune cells over to destroy them when they're infected. The researchers genetically engineered Ebola Zaire viruses so that they had mutations in four places in their genetic material that the researchers thought were important to the virus' ability to stop dendric cells from making proteins. The researchers made four different engineered Ebola Zaire viruses, each with mistakes in just one place in its genetic material. Signs and symptoms of Ebola usually begin suddenly with an influenza-like stage characterized by fatigue, fever, headaches, joint, muscle and abdominal pain. Vomiting, diarrhea and loss of appetite are also common. Less common symptoms include the following: sore throat, chest pain, hiccups, shortness of breath and trouble swallowing.The average time between contracting the infection and the start of symptoms (incubation period) is 8 to 10 days, but it can vary between 2 and 21 days. Skin manifestations may include a maculopapular rash (in about 50% of cases). Early symptoms of EVD may be similar to those of malaria, dengue fever or other tropical fevers, before the disease progresses to the bleeding phase. Vaccine and treatment

No licensed vaccine for EVD is available. Several vaccines are being tested, but none are available for clinical use.

Severely ill patients require intensive supportive care. Patients are frequently dehydrated and require oral rehydration with solutions containing electrolytes or intravenous fluids.

No specific treatment is available. New drug therapies are being evaluated.